 Alzheimer's disease, AD, is the most common form of neurodegenerative disease and disability in the elderly, estimated to account for 60-70% of all cases of dementia worldwide. It is characterized by synaptic dysfunction, cognitive decline, psychotic symptoms, chronic inflammatory environment within the central nervous system, CNS, activated microbial cells, and dysfunctional gut microbiota. The discovery that AD is a neuroinflammatory disease linked to innate immunity phenomena started in the early 90s by several authors, including the ICC's group that described, in 2004, the role of Interleukin-6-IL6, an AD-type phosphorylation of tau protein in deregulating the CDK5-P35 pathway. The theory of neuroimmunomodulation, published in 2008, proposed the onset and progression of degenerative diseases as a multi-component damage signals phenomena, suggesting the feasibility of multi-target therapies in AD. This article was authored by Malin Wangara, Malin Wangara, Malin Wangara, and others. We are article.tv, links in the description below.